CN Patent

CN115803028A — 用于治疗慢性肾病的齐泊腾坦和达格列净的组合

Assigned to AstraZeneca AB · Expires 2023-03-14 · 3y expired

What this patent protects

本披露涉及内皮素受体拮抗剂(ERA)齐泊腾坦与钠依赖性葡萄糖协同转运蛋白2(SGLT‑2)抑制剂达格列净组合，用于在治疗某些内皮素相关疾病中使用。

USPTO Abstract

本披露涉及内皮素受体拮抗剂(ERA)齐泊腾坦与钠依赖性葡萄糖协同转运蛋白2(SGLT‑2)抑制剂达格列净组合，用于在治疗某些内皮素相关疾病中使用。

Drugs covered by this patent

Tryvio (APROCITENTAN) · Idorsia

Patent Metadata

Patent number: CN115803028A
Jurisdiction: CN
Classification: —
Expires: 2023-03-14
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.